secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001193125-24-188977
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen announces positive Phase 2 data for PGN-EDO51 in DMD: exon skipping 2.15%, dystrophin increase
--------------------------------------------------------------------------------

- PGN-EDO51 5 mg/kg achieved mean exon skipping of 2.15% in biceps tissue at week 13 (n=3).
- Mean muscle-adjusted dystrophin level of 1.49% of normal, +0.70% from baseline; absolute dystrophin 0.61%, +0.26%.
- Drug well tolerated; no discontinuations, one mild AE resolved, no kidney or electrolyte issues.
- All three patients continue in long-term extension; 10 mg/kg cohort dosing ongoing with results expected in early 2025.
- CONNECT2 Phase 2 trial open in UK; US site expected by year-end; design being optimized based on data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000119312524188977/0001193125-24-188977-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000119312524188977/d879173d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-188977

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer